Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Clinical Perspectives of Theranostics

Version 1 : Received: 12 February 2021 / Approved: 15 February 2021 / Online: 15 February 2021 (14:55:01 CET)
Version 2 : Received: 18 February 2021 / Approved: 22 February 2021 / Online: 22 February 2021 (07:51:33 CET)

How to cite: Tamaki, N.; Okamoto, S.; Shiga, T. Clinical Perspectives of Theranostics. Preprints 2021, 2021020314 (doi: 10.20944/preprints202102.0314.v1). Tamaki, N.; Okamoto, S.; Shiga, T. Clinical Perspectives of Theranostics. Preprints 2021, 2021020314 (doi: 10.20944/preprints202102.0314.v1).

Abstract

Theranostics covers combination of diagnostic and therapeutic techniques for various cancers throughout body using suitable drug combination. This review covers well-known treatment of thyroid cancer and pheochromocytoma with I-131 compounds and also new radiopharmaceuticals for prostatic cancer and pancreatic cancer. Of particular, new trends toward patient outcome has been focused. The theranostics will become an ever-increasing part of clinical nuclear medicine these days.

Subject Areas

PET, Theranostics, Radiopharmaceuticals

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.